Small‐molecule inhibitors of NNMT have been developed in recent years and are discussed as therapeutics for metabolic diseases, such as diabetes, obesity and fatty liver disease.77 This evidence concerns the gene NNMT and obesity due to melanocortin 4 receptor deficiency.